GlassScriptPhysician profile
Punam Sheth
NPI 1942771266
$2,388.96
in general payments reported to CMS, 2019-2025
21 companies · $63.52 in 2025
The $63.52 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,069 · 2022: $780 · 2023: $362 · 2024: $114 · 2025: $63.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $539.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $694.46 | 2021-2024 | Haegarda |
| Glaxosmithkline, LLC. | $388.16 | 2021-2022 | |
| Pfizer INC. | $314.71 | 2021-2023 | |
| Biocryst US Sales Co., LLC | $120.25 | 2021-2023 | Orladeyo |
| Corium, LLC | $107.38 | 2023-2025 | Azstarys |
| Regeneron Healthcare Solutions, INC. | $92.70 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $85.88 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $83.01 | 2021-2023 | |
| Hikma Pharmaceuticals USA | $82.45 | 2021-2022 | |
| Eyevance Pharmaceuticals LLC | $59.09 | 2021 | |
| Optinose US, INC. | $51.48 | 2021 | |
| Octapharma USA, INC. | $43.96 | 2021 | |
| Kaleo, INC. | $41.56 | 2021 | |
| Grifols USA, LLC | $41.31 | 2022-2023 | Xembify |
| Teva Pharmaceuticals USA, INC. | $38.28 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $36.46 | 2021-2022 | |
| Adma Biomanufacturing LLC | $27.13 | 2021 | |
| Supernus Pharmaceuticals, INC. | $26.96 | 2024 | Qelbree |
| Pharming Healthcare, INC. | $21.14 | 2022 | |
| Hospira, INC. | $18.89 | 2022 | |
| Aimmune Therapeutics, INC. | $13.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Punam Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.